Literature DB >> 18817851

Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease.

M T Tadaiesky1, P A Dombrowski, C P Figueiredo, E Cargnin-Ferreira, C Da Cunha, R N Takahashi.   

Abstract

In addition to classic motor symptoms, Parkinson's disease (PD) is characterized by cognitive and emotional deficits, which have been demonstrated to precede motor impairments. The present study addresses the question of whether a partial degeneration of dopaminergic neurons using 6-hydroxydopamine (6-OHDA) in rats is able to induce premotor behavioral signs. The time-course of nigrostriatal damage was evaluated by tyrosine hydroxylase immunohistochemistry and the levels of dopamine, noradrenaline, and 5-HT in various brain regions were analyzed by high performance liquid chromatography (HPLC). Behavioral tests that assessed a variety of psychological functions, including locomotor activity, emotional reactivity and depression, anxiety and memory were conducted on 6-OHDA lesioned rats. Bilateral infusion of 6-OHDA in the striatum of rats caused early (1 week) damage of dopaminergic terminals in striatum and in cell bodies in substantia nigra pars compacta. The nigrostriatal lesion was accompanied by early loss of dopamine in the striatum, which remained stable through a 3-week period of observation. In addition, a late (3 weeks) loss of dopamine in the prefrontal cortex, but not in the hippocampus, was seen. Additional noradrenergic and serotonergic alterations were observed after 6-OHDA administration. The results indicated that 6-OHDA lesioned rats show decreased sucrose consumption and an increased immobility time in the forced swimming test, an anhedonic-depressive-like effect. In addition, an anxiogenic-like activity in the elevated plus maze test and cognitive impairments were observed on the cued version of the Morris water maze and social recognition tests. These findings suggest that partial striatal dopaminergic degeneration and parallel dopaminergic, noradrenergic and serotonergic alterations in striatum and prefrontal cortex may have caused the emotional and cognitive deficits observed in this rat model of early phase PD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18817851     DOI: 10.1016/j.neuroscience.2008.08.035

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  70 in total

Review 1.  Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.

Authors:  Karen L Eskow Jaunarajs; Mariana Angoa-Perez; Donald M Kuhn; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2010-07-06       Impact factor: 8.989

2.  Behavioral, neurochemical and histological alterations promoted by bilateral intranigral rotenone administration: a new approach for an old neurotoxin.

Authors:  Camila G Moreira; Janaína K Barbiero; Deborah Ariza; Patrícia A Dombrowski; Pamela Sabioni; Mariza Bortolanza; Claudio Da Cunha; Maria A B F Vital; Marcelo M S Lima
Journal:  Neurotox Res       Date:  2011-09-28       Impact factor: 3.911

3.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

4.  Dopamine depletion in either the dorsomedial or dorsolateral striatum impairs egocentric Cincinnati water maze performance while sparing allocentric Morris water maze learning.

Authors:  Amanda A Braun; Robyn M Amos-Kroohs; Arnold Gutierrez; Kerstin H Lundgren; Kim B Seroogy; Matthew R Skelton; Charles V Vorhees; Michael T Williams
Journal:  Neurobiol Learn Mem       Date:  2014-11-13       Impact factor: 2.877

5.  The Gender-Biased Effects of Intranasal MPTP Administration on Anhedonic- and Depressive-Like Behaviors in C57BL/6 Mice: the Role of Neurotrophic Factors.

Authors:  Marissa Giovanna Schamne; Josiel Mileno Mack; Morgana Moretti; Filipe Carvalho Matheus; Roger Walz; Laurence Lanfumey; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2018-05-28       Impact factor: 3.911

6.  Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice.

Authors:  Sara Ferrazzo; Ozge Gunduz-Cinar; Nadia Stefanova; Gabrielle A Pollack; Andrew Holmes; Claudia Schmuckermair; Francesco Ferraguti
Journal:  Neurobiol Dis       Date:  2019-01-21       Impact factor: 5.996

7.  Occurrence of depression and anxiety prior to Parkinson's disease.

Authors:  E L Jacob; N M Gatto; A Thompson; Y Bordelon; B Ritz
Journal:  Parkinsonism Relat Disord       Date:  2010-08-01       Impact factor: 4.891

8.  Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.

Authors:  Indrani Datta; S R Mekha; Alka Kaushal; Kavina Ganapathy; Rema Razdan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-29       Impact factor: 3.000

9.  Personality characteristics and motor skills attributed to occupations in Parkinson disease.

Authors:  Nicole M Gatto; Yvette Bordelon; Margaret Gatz; Beate Ritz
Journal:  Cogn Behav Neurol       Date:  2011-03       Impact factor: 1.600

10.  Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Argelia Esperanza Rojas-Mayorquin; Claudia P Figueiredo; Filipe C Matheus; Laure Ginestet; Caroline Chevarin; Elaine Del Bel; Raymond Mongeau; Michel Hamon; Laurence Lanfumey; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.